Early in the HIV epidemic, lipodystrophy, characterized by subcutaneous fat loss
(lipoatrophy), with or without central fat accumulation (lipohypertrophy), was recognized as a …

Aliment Pharmacol Ther 2011; 34: 274–285 Summary Background Non‐alcoholic fatty liver
disease (NAFLD) is a common cause of chronic liver disease, and its worldwide prevalence …

Increasing evidence suggests that metabolites produced by the gut microbiota play a crucial
role in host–microbe interactions. Dietary tryptophan ingested by the host enters the gut …

Objective: To identify the prevalence and risk factors of nonalcoholic fatty liver disease
(NAFLD), nonalcoholic steatohepatitis (NASH) and fibrosis in HIV-monoinfected patients …

Abstract Purpose of Review The proportion of overweight and obese persons with HIV
(PWH) has increased since the introduction of antiretroviral therapy (ART). We aim to …

Background De novo steatosis is the main criteria for non-alcoholic fatty liver disease
(NAFLD), which is becoming a clinically relevant comorbidity in HIV-infected patients. This …

Introduction: Efficient antiretroviral-treatment (ART) generally allows control of HIV infection.
However, persons-living-with-HIV (PLWH), when aging, present a high prevalence of …

Introduction of effective combined antiretroviral therapy has made HIV infection a chronic
illness. Substantial reductions in the number of AIDS-related deaths have been …

Background and Aims Liver disease remains a leading cause of morbidity and mortality
among people living with HIV (PLWH). Emerging data suggest that PLWH are at high risk for …

Background: Obesity is often associated with nonalcoholic fatty liver disease (NAFLD),
which refers to a large spectrum of hepatic lesions including fatty liver, nonalcoholic …